Moleculera Labs

[Available On-Demand]
We are a precision medicine company focused on neurologic, psychiatric and behavioral disorders. We perform blood testing that identifies autoimmune markers directed against portion of the brain resulting in a basal ganglia encephalitis (BGE) which is a root cause of portions of disorders such as Autism Spectrum Disorder (ASD), ADD/ADHD, bipolar disorder, anxiety disorder, Tourette’s, PANDAS/PANS and many other neuropsychiatric syndromes. Through our CLIA/COLA accredited clinical laboratory we test blood samples for 5 autoimmune antibodies attacking targets in the brain and CNS. Patients testing positive respond to anti-infective and immune modulation therapy who were previously unresponsive to traditional psychotropic and standard therapies. Over 60 million individuals in the U.S. are on psychotropic drugs.

We have a therapeutic target identification program based upon over 10,000 tests with clinical annotations in our databank, from 1,700 ordering doctors. We are seeking additional pharma partner interests as we have agreements with pharma and R&D partners for testing and identifying novel drug targets, as well as development of treatment predictive algorithms.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Oklahoma
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Cunningham Panel for Autoimmune Encephalopathies
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Moleculera Labs